{"id":"NCT04400760","sponsor":"The University of The West Indies","briefTitle":"The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.","officialTitle":"The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts: The EDGE Study.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-05-01","primaryCompletion":"2022-06-30","completion":"2022-06-30","firstPosted":"2020-05-26","resultsPosted":"2023-11-07","lastUpdate":"2023-11-07"},"enrollment":40,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Platelet Dysfunction"],"interventions":[{"type":"DRUG","name":"DAPA Tx","otherNames":[]}],"arms":[{"label":"DAPA Tx","type":"OTHER"}],"summary":"Sodium GLucose Transport 2 inhibitors (SGLT2I), including dapagliflozin, reduce the likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of which the mechanism has not been fully elucidated. The mechanistic effects of dapagliflozin on platelet function profiles have not yet been ascertained. It remains unclear if this reduction in cardiovascular death is mediated by decreased platelet reactivity.","primaryOutcome":{"measure":"Platelet Reactions Units Pre-DAPA Tx and Post-DAPA Tx","timeFrame":"Baseline (0 weeks) to Completion (2 weeks) after Dapagliflozin","effectByArm":[{"arm":"DAPA Tx","deltaMin":160.93,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Trinidad and Tobago"]},"refs":{"pmids":["34643895"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":[]}}